Protagenic Therapeutics, Inc.new (PTIXW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
149 FIFTH AVENUE NEW YORK, NY 10010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 4,056 | 7,979 | 10,371 | 671 | 799 | 362 | |||
| Cash and cash equivalent | 1,288 | 215 | 541 | 671 | 799 | 362 | |||
| Short-term investments | 2,768 | 7,764 | 9,830 | ||||||
| Prepaid expense | 144 | 208 | 43 | 83 | |||||
| Other undisclosed current assets | 57 | 689 | 250 | ||||||
| Total current assets: | 4,200 | 8,036 | 11,060 | 879 | 842 | 696 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 123 | 2 | 0 | 1 | |||||
| Total noncurrent assets: | 123 | 2 | 0 | 1 | |||||
| TOTAL ASSETS: | 4,323 | 8,037 | 11,060 | 879 | 842 | 697 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 120 | 670 | 500 | 572 | 865 | 232 | |||
| Accrued liabilities | 120 | 142 | 163 | 10 | |||||
| Other undisclosed accounts payable and accrued liabilities | 670 | 500 | 430 | 702 | 222 | ||||
| Debt | 151 | ||||||||
| Derivative instruments and hedges, liabilities | 84 | 332 | 676 | ||||||
| Due to related parties | ✕ | ✕ | 194 | ||||||
| Other undisclosed current liabilities | 535 | 106 | 300 | ||||||
| Total current liabilities: | 655 | 1,120 | 800 | 655 | 1,197 | 908 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 132 | 1,081 | 175 | ||||||
| Long-term debt, excluding current maturities | 132 | 1,081 | 175 | ||||||
| Liabilities, other than long-term debt | 186 | ||||||||
| Due to related parties | ✕ | ✕ | 186 | ||||||
| Other undisclosed noncurrent liabilities | 292 | 105 | |||||||
| Total noncurrent liabilities: | 318 | 1,374 | 279 | ||||||
| Total liabilities: | 655 | 1,120 | 1,118 | 2,029 | 1,477 | 908 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 3,668 | 6,918 | 9,942 | (1,150) | (634) | (211) | |||
| Common stock | 0 | 0 | 2 | 1 | 1 | 1 | |||
| Additional paid in capital | 34,559 | 33,371 | 32,410 | 16,720 | 14,687 | 13,358 | |||
| Accumulated other comprehensive loss | (114) | (677) | (248) | (172) | (172) | (171) | |||
| Accumulated deficit | (30,778) | (25,777) | (22,222) | (17,699) | (15,150) | (13,399) | |||
| Other undisclosed equity, attributable to parent | 0 | 0 | 0 | ||||||
| Total equity: | 3,668 | 6,918 | 9,942 | (1,150) | (634) | (211) | |||
| TOTAL LIABILITIES AND EQUITY: | 4,323 | 8,037 | 11,060 | 879 | 842 | 697 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other Operating Income) | 3 | |||||||
| Gross profit: | 3 | |||||||
| Operating expenses | (4,527) | (3,558) | (4,140) | (2,552) | (2,086) | (2,314) | ||
| Other undisclosed operating loss | (3) | |||||||
| Operating loss: | (4,527) | (3,558) | (4,140) | (2,552) | (2,086) | (2,314) | ||
| Nonoperating income (expense) | (474) | 2 | (383) | 3 | 335 | (243) | ||
| Investment income, nonoperating | 264 | 186 | 33 | |||||
| Other nonoperating expense | (246) | (13) | ||||||
| Interest and debt expense | (108) | (137) | (497) | (100) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 100 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (5,108) | (3,693) | (5,020) | (2,549) | (1,751) | (2,558) | ||
| Other undisclosed income from continuing operations before income taxes | 108 | 137 | 497 | |||||
| Loss from continuing operations: | (5,000) | (3,556) | (4,523) | (2,549) | (1,751) | (2,558) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (4,523) | (2,549) | (1,751) | (2,558) | |
| Net loss available to common stockholders, diluted: | (5,000) | (3,556) | (4,523) | (2,549) | (1,751) | (2,558) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (5,000) | (3,556) | (4,523) | (2,549) | (1,751) | (2,558) | ||
| Other comprehensive income (loss) | 5 | (6) | ||||||
| Comprehensive loss: | (5,000) | (3,556) | (4,523) | (2,549) | (1,746) | (2,564) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 563 | (429) | (77) | 1 | (11) | 4 | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,437) | (3,984) | (4,600) | (2,548) | (1,758) | (2,560) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.